Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer

Breast Cancer Research and Treatment

Volumn 135, Issue 3, 2012, Pages 885-892

  Heusinger, Katharina ^a,b   Jud, Sebastian M ^a,b   Häberle, Lothar ^a,b   Hack, Carolin C ^a,b   Fasching, Peter A ^a,b,c   Meier Meitinger, Martina ^d   Lux, Michael P ^a,b   Hagenbeck, Carsten ^a,b   Loehberg, Christian R ^a,b   Wittenberg, Thomas ^e   Rauh, Claudia ^a   Wagner, Florian ^e   Uder, Michael ^d   Hartmann, Arndt ^a   Schulz Wendtland, Rüdiger ^d   Beckmann, Matthias W ^a,b   Wachter, David L ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Friedrich Alexander University Erlangen Nuremberg   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e FRAUNHOFER INSTITUTE FOR INTEGRATED CIRCUITS IIS   (Germany)

Author keywords

Breast cancer; Estrogen receptor; Ki 67; Mammographic density; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; BODY MASS; BREAST CANCER; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; DENSITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHIC DENSITY; MENOPAUSE; PARITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

AGED; BODY MASS INDEX; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KI-67 ANTIGEN; MAMMOGRAPHY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866547252     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2221-3     Document Type: Article

References (34)

1. Liedtke C, Wolf MK, Kiesel L (2010) New concepts for targeted systemic therapy in breast cancer. Geburtsh Frauenheilkd 70(8):625-633. doi:10.1055/s-0030-1250182
2. Fasching PA, Ekici AB, Adamietz B et al (2011) Breast cancer risk-genes, environment, and clinical practice. Geburtsh Frauenheilkd 71(12):1056-1066. doi:10.1055/s-0031-1280437
3. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-183. doi:10.1016/S1470-2045(09)70262-1
4. Dowsett M, Nielsen TO, A'Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656-1664. doi:10.1093/jnci/djr393
5. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826. doi:10.1056/NEJMoa041588 (Pubitemid 40051905)
6. Cuzick J, Dowsett M, Pineda S et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273-4278. doi: 10.1200/JCO.2010.31.2835
7. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer.NEngl JMed 360(8):790-800. doi:10.1056/NEJMra0801289
8. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750. doi:10.1093/jnci/djp082
9. Fasching PA, Heusinger K, Haeberle L et al (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486. doi: 10.1186/1471-2407-11-486
10. Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triplenegative breast cancer. J Natl Cancer Inst 103(6):470-477. doi: 10.1093/jnci/djr030
11. Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250-263. doi:10.1093/jnci/djq526
12. Stacey SN, Manolescu A, Sulem P et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptorpositive breast cancer. Nat Genet 40(6):703-706. doi:10.1038/ ng.131 (Pubitemid 351748861)
13. Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39(7):865-869. doi:10.1038/ng2064 (Pubitemid 47014497)
14. Garcia-Closas M, Chanock S (2008) Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 14(24):8000-8009. doi:10.1158/1078-0432.CCR-08-0975
15. Garcia-Closas M, Hall P, Nevanlinna H et al (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4(4): e1000054. doi:10.1371/journal. pgen.1000054 (Pubitemid 351656691)
16. Thomas G, Jacobs KB, Kraft P et al (2009) A multistage genomewide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5):579-584. doi:10.1038/ng.353
17. Turnbull C, Ahmed S, Morrison J et al (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42(6):504-507. doi:10.1038/ng.586
18. Ahmed S, Thomas G, Ghoussaini M et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41(5):585-590. doi:10.1038/ng.354
19. Broeks A, Schmidt MK, Sherman ME et al (2011) Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20(16):3289-3303. doi:10.1093/hmg/ddr228
20. Antoniou AC, Beesley J, McGuffog L et al (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70(23):9742-9754. doi:10.1158/0008-5472.CAN-10-1907
21. Antoniou AC, Wang X, Fredericksen ZS et al (2010) A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42(10):885-892. doi: 10.1038/ng.669
22. Stevens KN, Vachon CM, Lee AM et al (2011) Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res 71(19):6240-6249. doi:10.1158/ 0008-5472.CAN-11-1266
23. McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis. Cancer Epidemiol Biomarkers Prev 15(6):1159-1169. doi:10.1158/1055-9965.EPI-06-0034
24. Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227-236. doi:10.1056/NEJMoa062790 (Pubitemid 46143226)
25. Heusinger K, Loehberg CR, Haeberle L et al (2011) Mammographic density as a risk factor for breast cancer in a German case-control study. Eur J Cancer Prev 20(1):1-8. doi:10.1097/ CEJ.0b013e328341e2ce
26. Yaghjyan L, Colditz GA, Collins LC et al (2011) Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst 103(15):1179-1189. doi:10.1093/jnci/djr225
27. Heusinger K, Jud SM, Haberle L et al (2012) Association of mammographic density with hormone receptors in invasive breast cancers-results from a case-only study. Int J Cancer. doi: 10.1002/ijc.27515
28. Aiello EJ, Buist DS, White E et al (2005) Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev 14(3):662-668. doi: 10.1158/1055-9965.EPI-04-0327 (Pubitemid 40489212)
29. Fasching PA, Heusinger K, Loehberg CR et al (2006) Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. Eur J Radiol 60(3):398-404. doi:10.1016/j.ejrad. 2006.08.002
30. Beckmann MW, Brucker C, Hanf V et al (2011) Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie 34(7):362-367. doi:10.1159/000329601
31. Ursin G, Astrahan MA, Salane M et al (1998) The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 7(1):43-47 (Pubitemid 28087141)
32. Blamey RW, Cataliotti L (2006) EUSOMA accreditation of breast units. Eur J Cancer 42(10):1331-1337. doi:10.1016/j.ejca. 2006.04.003 (Pubitemid 43903163)
33. Verheus M, Maskarinec G, Erber E et al (2009) Mammographic density and epithelial histopathologic markers. BMC Cancer 9:182. doi:10.1186/1471-2407-9- 182
34. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752. doi:10.1038/ 35021093